FundedIQ
Biotechnology

Generare: Funding, Investors & Team (Sep 2026)

Natural products have contributed more than 500 molecules to pharmaceuticals. However, conventional methods for discovering new natural products are increasingly ineffective. Generare has developed a revolutionary platform that identifies and expresses a wide range of naturally occurring secondary metabolites, selected by millions of years of bacterial evolution. This platform allows us to reintroduce these lead molecules into clinical pipelines, reopening a validated avenue for therapeutic innovation.

generare.bio LinkedIn Paris, France 1-10 employees
Total raised
$28.6M
Rounds
2
Latest
Series A
Apr 2026

Generare has raised $28.6M across 2 funding rounds on record, the most recent a Series A of $23.1M announced in Apr 2026.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Generare Company Profile and Key Stats

Total funding raised
$28.6M
across 2 rounds on record
Funding rounds on record
2
Latest funding round
Series A
$23.1M in Apr 2026
Employees
1-10
reported band
Headquarters
Paris, France

Latest funding round on record: Apr 2026.

Generare Funding Rounds

Date
Round
Amount
Series A
$23.1M
Seed
$5.5M

Generare raised $5.5M in a Seed announced in Oct 2024.

1.5 years later, a Series A of $23.1M was announced in Apr 2026.

Generare Founders and Leadership Team

Name
Role
Contact
Guillaume Vandenesch
Founder
Locked
Vincent Libis
Founder

Contact details for the Generare team: 1 of 2 have an email address on file.

Start 14-day free trial →

Generare Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,179
$8.0M
1,705
$6.7M
8,352
$15M

Generare's latest round of $23.1M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Generare in Biotechnology and Paris

Companies Similar to Generare

Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…

Series A $12.6M

TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…

Series D $34.0M

NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…

Undisclosed round $6.9M

Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…

Undisclosed round $1.7M

One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…

Undisclosed round

Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…

Undisclosed round $120M

NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…

Undisclosed round $8.4M

AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…

Undisclosed round $11.6M

Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…

Undisclosed round $116M

Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…

Undisclosed round $7.0M

Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…

Undisclosed round $45.0M

AB Science was established in 2001 by a group of individuals in the medical and business fields who are…

Undisclosed round $3.7M

Generare Funding FAQs

What does Generare do?

Natural products have contributed more than 500 molecules to pharmaceuticals. However, conventional methods for discovering new natural products are increasingly ineffective. Generare has developed a revolutionary platform that identifies and expresses a wide range of naturally occurring secondary metabolites, selected by millions of years of bacterial evolution. This platform allows us to reintroduce these lead molecules into clinical pipelines, reopening a validated avenue for therapeutic innovation.

How much funding has Generare raised?

Generare has raised $28.6M across 2 rounds on record. The most recent is a Series A of $23.1M announced in Apr 2026.

When did Generare last raise funding?

Generare's most recent funding round on record is a Series A of $23.1M, announced in Apr 2026.

Who founded Generare?

FundedIQ lists Guillaume Vandenesch (Founder), Vincent Libis (Founder) at Generare.

Where is Generare headquartered?

Generare is based in Paris, Ile-De-France, France.

How many employees does Generare have?

Generare is in the 1-10 employee band.

How does Generare's funding compare to other Biotechnology startups?

Generare's latest round of $23.1M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.

About FundedIQ's Generare Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Generare is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.